KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Depreciation & Amortization (CF) (2018 - 2025)

Vir Biotechnology (VIR) has disclosed Depreciation & Amortization (CF) for 8 consecutive years, with $2.9 million as the latest value for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) changed 0.42% to $2.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $11.7 million through Dec 2025, down 19.77% year-over-year, with the annual reading at $11.7 million for FY2025, 19.77% down from the prior year.
  • Depreciation & Amortization (CF) hit $2.9 million in Q4 2025 for Vir Biotechnology, down from $3.0 million in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $5.6 million in Q1 2023 to a low of $1.3 million in Q1 2021.
  • Historically, Depreciation & Amortization (CF) has averaged $2.9 million across 5 years, with a median of $2.9 million in 2024.
  • Biggest five-year swings in Depreciation & Amortization (CF): soared 302.71% in 2023 and later plummeted 36.53% in 2025.
  • Year by year, Depreciation & Amortization (CF) stood at $1.4 million in 2021, then soared by 68.0% to $2.4 million in 2022, then skyrocketed by 90.43% to $4.5 million in 2023, then tumbled by 35.57% to $2.9 million in 2024, then rose by 0.42% to $2.9 million in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for VIR at $2.9 million in Q4 2025, $3.0 million in Q3 2025, and $2.9 million in Q2 2025.